Nitrogen-containing bisphosphonates and cancer immunotherapy

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 3007-3014

  Clezardin P ^a   Massaia, M ^b  

^a UNIVERSITÉ LYON 1   (France)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Bisphosphonate; Cancer; Gamma delta T cell; Immunotherapy; IPP; Zoledronate

Indexed keywords

ANTIGEN; BISPHOSPHONIC ACID DERIVATIVE; BROMOHYDRIN PYROPHOSPHATE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INNACELL; INORGANIC PYROPHOSPHATASE; INTERLEUKIN 2; IPH 1101; MEVALONIC ACID; NITROGEN CONTAINING BIPHOSPHONATE; PAMIDRONIC ACID; PHOSPHOANTIGEN; PHOSPHOSTIM; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL EXPANSION; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG CYTOTOXICITY; HUMAN; INNATE IMMUNITY; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; METABOLITE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; NITROGEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78649861292     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563545     Document Type: Review

References (64)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-4.
2. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998; 13: 1668-78.
3. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-89.
4. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006; 103: 7829-34.
5. Rondeau JM, Bitsch F, Bourgier E, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMed- Chem 2006; 1: 267-73.
6. Mönkkönen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006; 147: 437-45.
7. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007; 257: 16-35.
8. Kabelitz D, Wesch D, He W. Perspectives of γδ T cells in tumor immunology. Cancer Res 2007; 67: 5-8.
9. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007; 215: 59-76.
10. Vantourout P, Mookerjee-Basu J, Rolland C, et al. Specific requirements for Vγ9Vδ2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol 2009; 183: 3848-57.
11. Gong G, Shao L, Wang Y, et al. Phosphoantigen-activated Vγ9Vδ2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. Blood 2009; 113: 837-45.
12. Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhem M. Inhibition of phosphoantigen-mediated γδ T-cell proliferation by CD4+CD25+FoxP3+ regulatory T cells. Immunology 2008; 126: 256-67.
13. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999; 340: 737-8.
14. Tanaka Y. Human γδ T cells and tumor immunotherapy. J Clin Exp Hematopathol 2006; 46: 11-23.
15. Caccamo N, Meraviglia S, Scarpa F, et al. Aminobisphosphonateactivated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther 2008; 8: 875-83.
16. Fiore F, Castella B, Nuschak B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007; 110: 921-7.
17. Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 2001; 166: 5508-14.
18. Roelofs AJ, Jauhiainen M, Mönkkönen H, Rogers MJ, Mönkkönen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009; 144: 245-50.
19. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19: 278-88.
20. Wei H, Huang D, Lai X, et al. Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vγ9Vδ2 TCR. J Immunol 2008; 181: 4798-806.
21. Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N. Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate. J Immunol 2003; 170: 3608-13.
22. Mönkkönen H, Kuokkanen J, Holen I, et al. Bisphosphonateinduced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008; 19: 391-9.
23. Li J, Herold MJ, Kimmel B, et al. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol 2009; 182: 8118-24.
24. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163-8.
25. Mariani S, Muraro M, Pantaleoni F, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19: 664-70.
26. Todaro M, D'Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182: 7287-96.
27. Uchida R, Ashihara E, Sato K, et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun 2007; 354: 613-8.
28. Kato Y, Tanaka Y, Hayashi M, Okawa K, Minato N. Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens. J Immunol 2006; 177: 877-84.
29. Alexander AA, Maniar A, Cummings JS, et al. Isopentenyl pyrophosphate- activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 2008; 14: 4232-40.
30. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116: 94-9.
31. Yuasa T, Sato K, Ashihara E, et al. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 2009; 58: 493-502.
32. D'Asaro M, La Mendola C, Di Liberto D, et al. Vgamma9Vdelta2 T lymphocytes efficiently recognize and kill zoledronatesensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010; 184: 3260-8.
33. Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human Vgamma9Vdelta2 T cells in vitro and in SCID mice in vivo. J Immunol 2004; 173: 6767-76.
34. Kondo M, Sakuta K, Noguchi A, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008; 10: 842-56.
35. Burjanadzé M, Condomines M, Reme T, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007; 139: 206-16.
36. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother 2007; 56: 1285-97.
37. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67: 7450-7.
38. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360(7): 679-91.
39. Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2009; [Epub ahead of print].
40. Di Carlo E, Diodoro MG, Boggio K, et al. Analysis of mammary carcinoma onset and progression in HER-2/neuoncogene transgenic mice reveals a lobular origin. Lab Invest 1999; 79(10): 1261-9.
41. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998 Feb; 16(2): 593-602.
42. Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S, Huerta- Guzmán J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24(2): 227-30.
43. Okamoto K, Tsurutani J, Terashima M, Okamoto I, Nakagawa K. Zoledronic acid-induced regression of multiple metastases at nonskeletal sites. Ann Oncol 2009; 20(4): 796-7.
44. Boudou-Rouquette P, Alexandre J, Soubrane O, Bertagna X, Goldwasser F. Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient. Ann Oncol 2009; 20(10): 1747.
45. Español I, Romagosa V, Berlanga J, et al. Zoledronate-induced remission of acute panmyelosis with myelofibrosis. Eur J Haematol 2004; 73(3): 215-8.
46. Corso A, Astori C, Orlandi E, Zappasodi P, Arcaini L, Bernasconi C. Transient response of myeloma clone to pamidronate therapy. Haematologica 1999; 84(8): 759-60.
47. Kondo H, Mori A. Anti-tumor activity of pamidronate in human multiple myeloma. Leuk Lymphoma 2002; 43(4): 919-21.
48. Puig N, Trudel S, Keats JJ, et al. Spontaneous remission in a patient with t(4; 14) translocation multiple myeloma. J Clin Oncol 2009; 27(33): e194-7.
49. Laggner U, Lopez JS, Perera G, et al. Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy. Clin Immunol 2009; 131(3): 367-73.
50. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102(1): 200-6.
51. Mahan CS, Thomas JJ, Boom WH, Rojas RE. CD4+ CD25(high) Foxp3+ regulatory T cells downregulate human Vdelta2+ Tlymphocyte function triggered by anti-CD3 or phosphoantigen. Immunology 2009; 127(3): 398-407.
52. Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003; 198(3): 391-7.
53. Dieli F, Gebbia N, Poccia F, et al. Induction of gamma delta Tlymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102(6): 2310-1.
54. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and antitumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007; 56(4): 469-76.
55. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008; 57(11): 1599-609.
56. Abe Y, Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cellbased immunotherapy for patients with multiple myeloma. Exp Hematol 2009; 37(8): 956-68.
57. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102: 9571-9576.
58. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626.
59. Angelini DF, Borsellino G, Poupot M, et al. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 2004; 104(6): 1801-7.
60. Tokuyama H, Hagi T, Mattarollo SR, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab. Int J Cancer 2008; 122(11): 2526-34.
61. Gertner-Dardenne J, Bonnafous C, Bezombes C, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009; 113(20): 4875-84.
62. Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA. Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma. Curr Pharm Des 2010; 16(11): 1272-83.
63. Holen I, Coleman RE. Bisphosphonates as Treatment of Bone Metastases. Curr Pharm Des 2010; 15(11): 1262-71.
64. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-58.